Key result
Undiluted Matrigel mattress increases hiPSC-cardiomyocyte shortening to ~9.0% vs. 0.4% in controls.
The Matrigel mattress method enables robust contractility and maturation in hiPSC-CMs, facilitating single-cell level quantification for basic research and preclinical cardiotoxicity testing.
Matrigel mattress culture may advance hiPSC-CM maturation for preclinical assays; leaves open clinical translation and in vivo validation.
RATIONALE: The lack of measurable single-cell contractility of human-induced pluripotent stem cell-derived cardiac myocytes (hiPSC-CMs) currently limits the utility of hiPSC-CMs for evaluating contractile performance for both basic research and drug discovery. OBJECTIVE: To develop a culture method that rapidly generates contracting single hiPSC-CMs and allows quantification of cell shortening with standard equipment used for studying adult CMs. METHODS AND RESULTS: Single hiPSC-CMs were cultured for 5 to 7 days on a 0.4- to 0.8-mm thick mattress of undiluted Matrigel (mattress hiPSC-CMs) and compared with hiPSC-CMs maintained on a control substrate (<0.1-mm thick 1:60 diluted Matrigel, control hiPSC-CMs). Compared with control hiPSC-CMs, mattress hiPSC-CMs had more rod-shape morphology and significantly increased sarcomere length. Contractile parameters of mattress hiPSC-CMs measured with video-based edge detection were comparable with those of freshly isolated adult rabbit ventricular CMs. Morphological and contractile properties of mattress hiPSC-CMs were consistent across cryopreserved hiPSC-CMs generated independently at another institution. Unlike control hiPSC-CMs, mattress hiPSC-CMs display robust contractile responses to positive inotropic agents, such as myofilament calcium sensitizers. Mattress hiPSC-CMs exhibit molecular changes that include increased expression of the maturation marker cardiac troponin I and significantly increased action potential upstroke velocity because of a 2-fold increase in sodium current (INa). CONCLUSIONS: The Matrigel mattress method enables the rapid generation of robustly contracting hiPSC-CMs and enhances maturation. This new method allows quantification of contractile performance at the single-cell level, which should be valuable to disease modeling, drug discovery, and preclinical cardiotoxicity testing.
No takes yet. Share an insight, caveat, or question.
Feaster et al. (2015) studied Human-induced pluripotent stem cell-derived cardiac myocytes (hiPSC-CMs). Undiluted Matrigel mattress vs. Control substrate (<0.1-mm thick 1:60 diluted Matrigel) was evaluated on Cellular shortening (p=<0.0001). Culturing human-induced pluripotent stem cell-derived cardiac myocytes on an undiluted Matrigel mattress significantly increased cell shortening to 9.0% compared to 0.4% in control cells (p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: